The current state of biomarkers in systemic sclerosis

Current Rheumatology Reports

Volumn 12, Issue 1, 2010, Pages 34-39

  Hummers, Laura K ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Biomarkers; Fibrosis; Pulmonary hypertension; Scleroderma

Indexed keywords

ANGIOGENIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CARBON MONOXIDE; CELL ADHESION MOLECULE;

COLLAGEN METABOLISM; DISEASE ACTIVITY; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; FIBROSIS; HUMAN; LUNG DIFFUSION CAPACITY; LUNG LAVAGE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REVIEW; RISK ASSESSMENT; SCLERODERMA; SIGNAL TRANSDUCTION; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE; VASCULAR DISEASE;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; HYPERTENSION, PULMONARY; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC;

EID: 77249118710     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-009-0081-6     Document Type: Review

References (49)

1. H Penn AJ Howie EJ Kingdon, et al. 2007 Scleroderma renal crisis: patient characteristics and long-term outcomes QJM 100 485 494 10.1093/qjmed/hcm052 1:STN:280:DC%2BD2svjtVWgtQ%3D%3D 17601770 (Pubitemid 47241915)
2. G Valentini W Bencivelli S Bombardieri, et al. 2003 European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria Ann Rheum Dis 62 901 903 10.1136/ard.62.9.901 1:STN:280:DC%2BD3svgsVaisg%3D%3D 12922968 (Pubitemid 37026505)
3. M Dziadzio W Usinger A Leask, et al. 2005 N-terminal connective tissue growth factor is a marker of the fibrotic phenotype in scleroderma QJM 98 485 492 10.1093/qjmed/hci078 1:STN:280:DC%2BD2MzksVSntA%3D%3D 15955800 (Pubitemid 41418671)
4. S Sato T Nagaoka M Hasegawa, et al. 2000 Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis J Rheumatol 27 149 154 1:CAS:528:DC%2BD3cXos1Kgug%3D%3D 10648031
5. M Dziadzio RE Smith DJ Abraham, et al. 2005 Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score Rheumatology (Oxford) 44 1518 1524 10.1093/rheumatology/kei088 1:CAS:528:DC%2BD2MXht1GltrzE (Pubitemid 41742468)
6. •• Sargent JL, Milano A, Bhattacharyya S, et al.: A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol 2009 Oct 8 (Epub ahead of print). This study used data from in vitro studies of scleroderma fibroblasts to develop a mechanistically derived gene expression profile. This TGF-β responsive gene signature from skin biopsies correlated with the diffuse subset of scleroderma and with more significant skin and lung disease.
7. L Chung DF Fiorentino MJ Benbarak, et al. 2009 Molecular framework for response to imatinib mesylate in systemic sclerosis Arthritis Rheum 60 584 591 10.1002/art.24221 1:CAS:528:DC%2BD1MXjt1Cnsrk%3D 19180499
8. CP Denton PA Merkel DE Furst, et al. 2007 Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192 Arthritis Rheum 56 323 333 10.1002/art.22289 1:CAS:528:DC%2BD2sXhsFaisL8%3D 17195236 (Pubitemid 46106206)
9. T Krieg JS Perlish R Fleischmajer O Braun-Falco 1985 Collagen synthesis in scleroderma: selection of fibroblast populations during subcultures Arch Dermatol Res 277 373 376 10.1007/BF00509236 1:STN:280:DyaL2M3nvVejuw%3D%3D 4026379 (Pubitemid 15059779)
10. CM Black A McWhirter NK Harrison, et al. 1989 Serum type III procollagen peptide concentrations in systemic sclerosis and Raynaud's phenomenon: relationship to disease activity and duration Br J Rheumatol 28 98 103 10.1093/rheumatology/28.2.98 1:STN:280:DyaL1M3gvVSqsA%3D%3D 2706431
11. E Diot P Diot C Valat, et al. 1995 Predictive value of serum III procollagen for diagnosis of pulmonary involvement in patients with scleroderma Eur Respir J 8 1559 1565 10.1183/09031936.95.08081263 1:STN:280: DyaK287itVSnsQ%3D%3D 8575585
12. A Scheja M Wildt FA Wollheim, et al. 2000 Circulating collagen metabolites in systemic sclerosis. Differences between limited and diffuse form and relationship with pulmonary involvement Rheumatology (Oxford) 39 1110 1113 10.1093/rheumatology/39.10.1110 1:CAS:528:DC%2BD3cXnvVKrt7c%3D
13. L Heickendorff H Zachariae P Bjerring, et al. 1995 The use of serologic markers for collagen synthesis and degradation in systemic sclerosis J Am Acad Dermatol 32 584 588 10.1016/0190-9622(95)90341-0 1:STN:280:DyaK2M3gsVKgtg%3D%3D 7896946
14. M Dziadzio RE Smith DJ Abraham, et al. 2004 Serological assessment of type I collagen burden in scleroderma spectrum disorders: a systematic review Clin Exp Rheumatol 22 356 367 1:STN:280:DC%2BD2c3ksFKrtw%3D%3D 15144134
15. B White WC Moore FM Wigley, et al. 2000 Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis Ann Intern Med 132 947 954 1:CAS:528:DC%2BD3cXkslylsb8%3D 10858177
16. C Strange MB Bolster MD Roth, et al. 2008 Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease Am J Respir Crit Care Med 177 91 98 10.1164/rccm.200705-655OC 1:CAS:528: DC%2BD1cXht12mt7k%3D 17901414
17. K Yanaba M Hasegawa K Takehara S Sato 2004 Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis J Rheumatol 31 1112 1120 1:CAS:528:DC%2BD2cXlsFWgt74%3D 15170923
18. FN Hant A Ludwicka-Bradley HJ Wang, et al. 2009 Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma J Rheumatol 36 773 780 10.3899/jrheum.080633 1:CAS:528: DC%2BD1MXkvFemt7c%3D 19286849 In this study, serum collected from patients in the Scleroderma Lung Study was examined for these two glycoproteins that are secreted by pneumocytes. Researchers showed clear correlations of these markers with clinical measures of active lung disease in scleroderma including CT evidence of ground glass, BAL fluid cytology, and pulmonary function
19. IG Luzina SP Atamas R Wise, et al. 2002 Gene expression in bronchoalveolar lavage cells from scleroderma patients Am J Respir Cell Mol Biol 26 549 557 1:CAS:528:DC%2BD38XjsFWkt7s%3D 11970906
20. M Kodera M Hasegawa K Komura, et al. 2005 Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis Arthritis Rheum 52 2889 2896 10.1002/art.21257 1:CAS:528:DC%2BD2MXhtFeltrnL 16142750 (Pubitemid 41369120)
21. A Prasse DV Pechkovsky GB Toews, et al. 2007 CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis Arthritis Rheum 56 1685 1693 10.1002/art.22559 1:CAS:528: DC%2BD2sXmsFartb8%3D 17469163 (Pubitemid 46764100)
22. MT Carulli C Handler JG Coghlan, et al. 2008 Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis? Ann Rheum Dis 67 105 109 10.1136/ard.2006.067967 1:CAS:528: DC%2BD1cXhs1ejtLc%3D 17604287 In this large cross-sectional study, the chemokine CCL2 was noted to be elevated in scleroderma and levels correlated with fibrotic disease features. This marker is notable for having clear variability with phenotype being higher in those with earlier, active disease
23. VD Steen 2005 Autoantibodies in systemic sclerosis Semin Arthritis Rheum 35 35 42 10.1016/j.semarthrit.2005.03.005 1:CAS:528:DC%2BD2MXntVOisL0%3D 16084222 (Pubitemid 41111469)
24. V Steen TA Medsger Jr 2003 Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement Arthritis Rheum 48 516 522 10.1002/art.10775 12571862 (Pubitemid 36278021)
25. Biomarkers Definitions Working Group 2001 Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin Pharmacol Ther 69 89 95 10.1067/mcp.2001.113989 (Pubitemid 32225406)
26. M Peters-Golden RA Wise MC Hochberg, et al. 1984 Carbon monoxide diffusing capacity as predictor of outcome in systemic sclerosis Am J Med 77 1027 1034 10.1016/0002-9343(84)90183-9 1:STN:280:DyaL2M%2FmvFGhsA%3D%3D 6507456 (Pubitemid 15221764)
27. C Morgan C Knight M Lunt, et al. 2003 Predictors of end stage lung disease in a cohort of patients with scleroderma Ann Rheum Dis 62 146 150 10.1136/ard.62.2.146 1:STN:280:DC%2BD3s%2FhvVOhsQ%3D%3D 12525384 (Pubitemid 36135390)
28. E Hachulla P de Groote V Gressin, et al. 2009 The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France Arthritis Rheum 60 1831 1839 10.1002/art.24525 19479881
29. Y Allanore D Borderie J Avouac, et al. 2008 High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis Arthritis Rheum 58 284 291 10.1002/art.23187 1:CAS:528:DC%2BD1cXhslOjtbg%3D 18163505 This is the first study to examine biomarkers to predict the development of pulmonary vascular disease in a prospective cohort study. Elevated levels of NT-proBNP predicted development of pulmonary vascular disease in this cohort
30. Dimitroulas T, Giannakoulas G, Karvounis H, et al.: Natriuretic peptides in systemic sclerosis-related pulmonary arterial hypertension. Semin Arthritis Rheum 2009 Jun 16 (Epub ahead of print).
31. Mathai SC, Hassoun PM: N-terminal brain natriuretic peptide in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2007, 28:140-141; author reply 141.
32. MH Williams CE Handler R Akram, et al. 2006 Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension Eur Heart J 27 1485 1494 10.1093/eurheartj/ehi891 1:CAS:528:DC%2BD28Xnt1Giu7o%3D 16682379 (Pubitemid 43998084)
33. R Sgonc MS Gruschwitz H Dietrich, et al. 1996 Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma J Clin Invest 98 785 792 10.1172/JCI118851 1:CAS:528: DyaK28XkvVeis7g%3D 8698871
34. AL Herrick K Illingworth A Blann, et al. 1996 Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis Ann Rheum Dis 55 122 127 10.1136/ard.55.2.122 1:STN:280:DyaK283mtlGktw%3D%3D 8712862
35. Hesselstrand R, Ekman R, Eskilsson J, et al.: Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001. Rheumatology (Oxford) 2005, 44:366-371
36. Published erratum appears in Rheumatology [Oxford] 2005, 44:569.
37. F Iannone MT Riccardi S Guiducci, et al. 2008 Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension Ann Rheum Dis 67 1121 1126 10.1136/ard.2007.080424 1:CAS:528:DC%2BD1cXhtVSktbjM 18029384
38. DJ Abraham R Vancheeswaran MR Dashwood, et al. 1997 Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease Am J Pathol 151 831 841 1:STN:280:DyaK2svjtVOhtw%3D%3D 9284832
39. S Morelli C Ferri L Di Francesco, et al. 1995 Plasma endothelin-1 levels in patients with systemic sclerosis: influence of pulmonary or systemic arterial hypertension Ann Rheum Dis 54 730 734 10.1136/ard.54.9.730 1:CAS:528: DyaK2MXoslShs74%3D 7495344
40. X Shi-Wen EA Renzoni L Kennedy, et al. 2007 Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts Matrix Biol 26 625 632 10.1016/j.matbio.2007.06.003 17681742 (Pubitemid 350186096)
41. RJ Stratton JG Coghlan JD Pearson, et al. 1998 Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma QJM 91 561 566 10.1093/qjmed/91.8.561 1:STN:280:DyaK1M7gvFOmtQ%3D%3D 9893759
42. MJ Mulligan-Kehoe MC Drinane J Mollmark, et al. 2007 Antiangiogenic plasma activity in patients with systemic sclerosis Arthritis Rheum 56 3448 3458 10.1002/art.22861 1:CAS:528:DC%2BD2sXht12rtLfN 17907150 In this article, the authors demonstrate that plasma from scleroderma patients is angiostatic in in vitro models of angiogenesis. Angiostatin appears to be at least partially responsible for this abnormality and levels of this molecule are noted to be elevated in scleroderma plasma (Pubitemid 47585441)
43. O Distler A Del Rosso R Giacomelli, et al. 2002 Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers Arthritis Res 4 R11 10.1186/ar596 12453314
44. LK Hummers A Hall FM Wigley M Simons 2009 Abnormalities in the regulators of angiogenesis in patients with scleroderma J Rheumatol 36 576 582 10.3899/jrheum.080516 19228661
45. O Distler JH Distler A Scheid, et al. 2004 Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis Circ Res 95 109 116 10.1161/01.RES.0000134644.89917.96 1:CAS:528:DC%2BD2cXlt1Cru7Y%3D 15178641 (Pubitemid 38931842)
46. M Hebbar JP Peyrat L Hornez, et al. 2000 Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis Arthritis Rheum 43 889 893 10.1002/1529-0131(200004)43:4<889::AID- ANR21>3.0.CO;2-5 1:CAS:528:DC%2BD3cXivFOit7w%3D 10765935 (Pubitemid 30677581)
47. J Wipff J Avouac D Borderie, et al. 2008 Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin Rheumatology (Oxford) 47 972 975 10.1093/rheumatology/ken100 1:CAS:528:DC%2BD1cXnsF2ksrc%3D Soluble endoglin is notable for having predictive capability in other disease states. In this study, the authors show that soluble endoglin strikingly correlates with a particular phenotype in scleroderma that associates with vascular disease (centromere antibody, digital ulcers, low DLCO), making this a very exciting biomarker candidate (Pubitemid 351865917)
48. Hummers LK, Simons M, Wigley FM, Mulligan-Kehoe MJ: Circulating inhibitors of angiogenesis in scleroderma. Presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology. Philadelphia, PA; October 16-21, 2009.
49. A Wang S Rana SA Karumanchi 2009 Preeclampsia: the role of angiogenic factors in its pathogenesis Physiology (Bethesda) 24 147 158